RT Journal Article SR Electronic T1 Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP 1802049 DO 10.1183/13993003.02049-2018 VO 53 IS 3 A1 François Maltais A1 Joseph-Leon Aumann A1 Anne-Marie Kirsten A1 Éric Nadreau A1 Hemani Macesic A1 Xidong Jin A1 Alan Hamilton A1 Denis E. O'Donnell YR 2019 UL http://erj.ersjournals.com/content/53/3/1802049.abstract AB The 3-min constant speed shuttle test (CSST) was used to examine the effect of tiotropium/olodaterol compared with tiotropium at reducing activity-related breathlessness in patients with chronic obstructive pulmonary disease (COPD).This was a randomised, double-blind, two-period crossover study including COPD patients with moderate to severe pulmonary impairment, lung hyperinflation at rest and a Mahler Baseline Dyspnoea Index <8. Patients received 6 weeks of tiotropium/olodaterol 5/5 µg and tiotropium 5 µg in a randomised order with a 3-week washout period. The speed for the 3-min CSST was determined for each patient such that an intensity of breathing discomfort ≥4 (“somewhat severe”) on the modified Borg scale was reached at the end of a completed 3-min CSST.After 6 weeks, there was a decrease in the intensity of breathlessness (Borg dyspnoea score) at the end of the 3-min CSST from baseline with both tiotropium (mean –0.968, 95% CI −1.238– −0.698; n=100) and tiotropium/olodaterol (mean −1.325, 95% CI −1.594– −1.056; n=101). The decrease in breathlessness was statistically significantly greater with tiotropium/olodaterol versus tiotropium (treatment difference −0.357, 95% CI −0.661– −0.053; p=0.0217).Tiotropium/olodaterol reduced activity-related breathlessness more than tiotropium in dyspnoeic patients with moderate to severe COPD exhibiting lung hyperinflation.Tiotropium/olodaterol reduces activity-related breathlessness versus tiotropium in COPD http://ow.ly/MVyk30niV1o